VANCOUVER, BC, October 29, 2010 – CRH Medical Corporation (CRM:TSX-V, CRMMF: OTCQX) announced today unaudited results for the three and nine months ended September 30, 2010. Total revenue for the three and nine months ended September 30, 2010 was $1,820,553 and $5,533,308 respectively compared to $1,758,382 and $5,357,077 for the same periods in 2009. The Company also reported a net loss of $228,919 and $994,157 for the three and nine months ended September 30, 2010 compared to $429,860 and $1,497,609 for the same periods in 2009.
As of September 30, 2010 the Company had $1,722,210 in cash and cash equivalents and $2,189,118 in working capital. As of December 31, 2009 the Company had $1,672,512 in cash and cash equivalents and $2,239,729 in working capital.
Edward Wright, Chief Executive Officer of CRH Medical states, “The revenue and operating income generated by our Partnership Program continues to grow as we increase the number of physicians trained and execute programs to increase adaption of the physicians we have already trained.” Wright further states, “To date we have trained 648 of the over 8,000 gastroenterologists in the United States. Demand for trainings continues to grow. During the first nine months of 2010, we trained 262 physicians compared to 167 physicians for the first nine months of 2009.”
The Company’s September 30, 2010 financial report will be available on www.sedar.com
About CRH Medical Corporation:
CRH Medical Corporation specializes in the treatment of hemorrhoids utilizing its proven treatment protocol and patented proprietary technology. CRH’s single use, disposable, hemorrhoid technology is safe and highly effective in treating hemorrhoid grades I – IV. CRH employs two commercialization strategies: first, CRH distributes its hemorrhoid banding technology, treatment protocols, operational and marketing expertise as a complete, turn key package directly to its partner physicians (“Partnership Program”). In addition, CRH operates Centers for Colorectal Health facilities in the United States specializing in the treatment of hemorrhoids, fissures, and colon cancer screening. The Company currently operates eight Centers geographically dispersed through the U.S.. The Company’s goal is to establish the CRH O’Regan System as the standard for hemorrhoid treatment.
The information in this news release contains so-called “forward-looking” statements. These include statements regarding CRH Medical’s expectations and plans relating to its business and statements about CRH Medical’s expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as “anticipate”, “expect”, “intend”, “plan”, “will”, “we believe”, “CRH Medical believes”, “management believes”, and similar language. All forward-looking statements are based on CRH Medical’s current expectations and are subject to risks and uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) we may need to raise additional capital to fund future operations; (ii) the policies of health insurance carriers in the United States may affect the amount of revenue the Company receives; (iii) the Company may not successfully market its products; (iv) changes in United States federal or state laws, rules, and regulations, including those governing the corporate practice of medicine, and fee splitting; (v) changes in the United States Anti-Kickback Statute and Stark Law and/or similar state laws, rules, and regulations; (vi) if we are unable to manage growth, we may be unable to achieve our expansion strategy: (vii) our senior management has been key to our growth, and we may be adversely affected if we lose any member of our senior management; (viii) economic dependence on suppliers and our contract manufacturer; (ix) changes in the industry and the economy may affect the Company’s business; (x) evolving regulation of corporate governance and public disclosure may result in additional corporate expenses; (xi) we may not be able to attract Gastroenterologists and other licensed providers to purchase and use the CRH O’Regan System; (xii) we may be subject to competition and technological risk which may impact the price and amount of product we can sell; (xiii) we may not be able to retain sufficient qualified physicians to operate our Centers; (xiv) we may be subject to product liability and medical malpractice claims, which may adversely affect our operations; (xv) our business may be impacted by health care reform in the United States; and (xvi) we may not have the expertise required to expand internationally. CRH Medical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.
For further information call Dean Linden, Corporate Communications, CRH Medical Corporation at 604.633.1440 or firstname.lastname@example.org. Additional information may also be found by visiting the Company’s website at www.crhmedcorp.com or the SEDAR website at www.sedar.com.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.